Amadori S, Petti M C, De Francesco A, Chierichini A, Mastrovincenzo C, Testa M G, Mandelli F
Cancer. 1978 Mar;41(3):1154-60. doi: 10.1002/1097-0142(197803)41:3<1154::aid-cncr2820410353>3.0.co;2-e.
The prognostic significance of the pretreatment growth characteristics of marrow blasts was examined in 37 patients with acute nonlymphocytic leukemia (ANLL) treated with a similar therapeutic regimen. Initial mitotic index (MI) and in vitro 3H-thymidine labeling index (LI) were broadly distributed showing no correlation to other initial variables, such as age or absolute blast count. No relationship whatsoever was observed between the pretreatment LI, MI and either the likelihood of achieving a complete remission or the remission and survival length. We conclude that the initial growth characteristics of marrow blasts do not play a significant role in predicting the therapeutic response in ANLL; age, modality of therapy and, possibly, the dynamic perturbations of the proliferative activity of the blast cells induced by treatment should be regarded as more reliable prognostic indicators in ANLL.
对37例接受相似治疗方案的急性非淋巴细胞白血病（ANLL）患者，研究了治疗前骨髓母细胞生长特征的预后意义。初始有丝分裂指数（MI）和体外3H-胸腺嘧啶核苷标记指数（LI）分布广泛，与其他初始变量如年龄或原始细胞绝对计数无相关性。治疗前LI、MI与达到完全缓解的可能性或缓解及生存时间之间均未观察到任何关系。我们得出结论，骨髓母细胞的初始生长特征在预测ANLL的治疗反应中不起重要作用；年龄、治疗方式以及可能由治疗诱导的原始细胞增殖活性的动态扰动，应被视为ANLL中更可靠的预后指标。
